Tweedy Browne Co LLC Has $156.26 Million Position in Johnson & Johnson (NYSE:JNJ)

Tweedy Browne Co LLC lessened its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,080,471 shares of the company's stock after selling 45,711 shares during the period. Johnson & Johnson makes up 10.5% of Tweedy Browne Co LLC's holdings, making the stock its 3rd largest position. Tweedy Browne Co LLC's holdings in Johnson & Johnson were worth $156,258,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Invenio Wealth Partners LLC lifted its holdings in Johnson & Johnson by 3.7% in the 4th quarter. Invenio Wealth Partners LLC now owns 3,404 shares of the company's stock valued at $492,000 after acquiring an additional 120 shares during the last quarter. Lokken Investment Group LLC boosted its holdings in Johnson & Johnson by 1.7% during the fourth quarter. Lokken Investment Group LLC now owns 15,199 shares of the company's stock worth $2,198,000 after buying an additional 247 shares in the last quarter. Geode Capital Management LLC grew its position in Johnson & Johnson by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after buying an additional 1,561,036 shares during the last quarter. Nemes Rush Group LLC increased its holdings in shares of Johnson & Johnson by 14.6% in the fourth quarter. Nemes Rush Group LLC now owns 55,954 shares of the company's stock valued at $8,092,000 after buying an additional 7,114 shares in the last quarter. Finally, StoneX Group Inc. boosted its stake in shares of Johnson & Johnson by 40.5% during the 4th quarter. StoneX Group Inc. now owns 42,849 shares of the company's stock worth $6,197,000 after acquiring an additional 12,359 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Wells Fargo & Company dropped their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Finally, Argus raised Johnson & Johnson to a "strong-buy" rating in a research report on Friday, January 24th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $171.33.

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded down $3.99 during trading hours on Friday, reaching $155.83. 6,107,234 shares of the company were exchanged, compared to its average volume of 9,408,155. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average of $159.63 and a 200 day moving average of $156.01. The firm has a market cap of $375.53 billion, a price-to-earnings ratio of 23.43, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.29 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.